Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	320.22	139.49	144.39	87.88	149.1
Cash & Short-Term Investments	320.22	139.49	144.39	87.88	149.1
Cash Growth	129.57%	-3.40%	64.30%	-41.06%	-40.66%
Other Current Assets	4.43	2.65	5.48	8.54	10.5
Total Current Assets	324.65	142.13	149.87	96.42	159.6
Net Property, Plant & Equipment	16.18	15.87	20.41	25.91	50.61
Other Long-Term Assets	2.5	2.37	2.46	3.95	3.74
Total Assets	343.32	160.36	172.73	126.28	213.96
Accounts Payable	6.28	3.59	6.37	10.95	21.76
Accrued Expenses	20.28	12.86	12.28	18.29	29.98
Unearned Revenue	-	9.77	18.11	33.56	-
Total Current Liabilities	26.55	26.23	36.76	62.79	51.75
Long-Term Debt	50.11	43.94	40.51	37.97	37.19
Long-Term Leases	18.17	17.36	18.95	20.44	25.9
Other Long-Term Liabilities	1.55	1.31	1.58	4.13	3.74
Total Long-Term Liabilities	69.83	62.61	61.04	62.54	66.83
Total Liabilities	96.38	88.84	97.79	125.33	118.57
Common Stock	0	0	0	0	-
Additional Paid-in Capital	958.43	677.86	587.94	402.39	331.03
Accumulated Other Comprehensive Income	-0.19	-4.03	-	-	-
Retained Earnings	-711.3	-602.31	-513.01	-401.44	-235.65
Shareholders' Equity	246.94	71.53	74.94	0.95	95.38
Total Liabilities & Equity	343.32	160.36	172.73	126.28	213.96
Total Debt	68.28	61.3	59.46	58.41	63.09
Net Cash (Debt)	251.94	78.18	84.93	29.47	86.01
Net Cash Growth	222.25%	-7.94%	188.16%	-65.73%	-65.77%
Net Cash Per Share	0.79	0.31	0.73	0.67	2.28
Book Value	246.94	71.53	74.94	0.95	95.38
Book Value Per Share	0.77	0.29	0.65	0.02	2.53
Tangible Book Value	246.94	71.53	74.94	0.95	95.38
Tangible Book Value Per Share	0.77	0.29	0.65	0.02	2.53

Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q